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ABSTRACT
HbA1c is an established index of glycaemic control and correlates strongly with risk of chronic diabetic 
complications. However, the accuracy of HbA1c measurement can be affected by many factors, 
among which is the presence of haemoglobin (Hb) variants. The aim of the study was to determine 
the percentage of Hb variant detected during HbA1c monitoring in Hospital Kuala Lumpur. The study 
also analysed non-reportable HbA1c results in the presence of Hb variants. A cross-sectional study 
using retrospective data of HbA1c results over fi ve months’ period was analysed on Biorad Variant 
II Turbo, a high performance liquid chromatography (HPLC) assay. The Hb variants were grouped 
either as HbS, HbC, others (Hb variant apart from HbS or C), and a combination of HbS or C with 
Others. A total of 11,904 patients were included. Only 2.3% (273) had Hb variants; HbS trait (10.3%), 
others (89%), and the combination of HbS trait with others (0.7%). No patient with HbC variant or 
its combination was found. Only 2.2% of those with Hb variant had non-reportable HbA1c. Although 
the percentage of Hb variants detected during HbA1c analysis and non-reportable HbA1c results were 
low, their presence should be noted.
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INTRODUCTION
Haemoglobin (Hb) A1c (HbA1c) is an established index of glycaemic control in patients with diabetes mellitus 
(DM), refl ecting average glucose over the preceding 2-3 months[1,2]. HbA1c concentration correlates strongly with 
the risk of chronic diabetic complications[3,4] and it is an important component in management of patients with 
DM[2,5].
HbA1c is produced by non-enzymatic addition of a glucose molecule to the N-terminal valine residue on the 
β-chain of Hb A. It constitutes a major portion of glycated Hb. Formation of HbA1c depends both on the lifespan 
of red blood cell (RBC) and plasma glucose concentration. Thus, conditions affecting RBC turnover (such as 
haemolytic anaemia and massive blood loss) will adversely affect HbA1c formation[6].
 Hb variants are abnormal forms of Hb. They arise from point mutation either in α, β, δ or γ Hb chains. More 
than 1000 Hb variants have been identifi ed with half being clinically silent[7]. The common Hb variants are HbS, 
HbE, HbC, and HbD. Individuals with homozygous Hb variant usually have reduced RBC lifespan and therefore, 
HbA1c is not recommended as a measure of glycaemic control in these patients. However, those with heterozygous 
diseases, such as HbS, HbC and HbE traits, as well as other clinically silent Hb variants, can potentially affect the 
accuracy of HbA1c measurement, the effect of which is HbA1c method dependent[6]. Meanwhile, the presence of 
elevated HbF can also affect HbA1c measurement.
High performance liquid chromatography (HPLC) and immunoassays are the two most common methods 
used in clinical laboratories[1, 6]. Ion-exchange HPLC identifi es HbA1c based on charge differences between HbA1c 
and other Hb[6]. Hb variants that cannot be separated from HbA or HbA1c will produce spuriously increased or 
decreased HbA1c results by ion-exchange HPLC[6]. Immunoassay measures HbA1c by using specifi c antibodies 
towards the N-terminal glycated amino acids of Hb β chain. Most immunoassays avoid spurious results for several 
Hb variants, but interference can occur depending on the antibody and assay used. The presence of Hb variant 
cannot be detected when using an immunoassay method for HbA1c[6].
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The laboratory should be aware of the effects of common Hb variant on the HbA1c method used and 
physicians should be alerted on the presence of these interferences. Incorrect reporting of HbA1c result can lead 
to mismanagement of diabetes as the results are used for treatment decision. Therefore, the objective of this study 
was to determine the percentage of Hb variant detected through HbA1c monitoring and its interrelated factors in 
the patient population of Hospital Kuala Lumpur (HKL).
MATERIALS AND METHODS
A cross-sectional study using retrospective data of HbA1c results over a fi ve-month’s period of all patients who had 
their HbA1c measurement at the Chemical Pathology Laboratory of HKL. The HbA1c reports and demographic 
data were retrieved from the laboratory information system (LIS). Only one HbA1c result per patient was included 
in the study. Meanwhile, repeated HbA1c result from the same patient was excluded.
HbA1c is measured on Biorad Variant II Turbo by using the HPLC method. Hb variant is identifi ed if the 
chromatogram, which is reviewed during reporting, showed abnormal peaks such as unknown peaks after or before 
the A0, variant window peak after A0, S-window or C-window. The laboratory routinely reports the presence of Hb 
variant discovered during HbA1c measurement with an additional comment such as ‘Hb variant detected. Suggest 
Hb analysis for confi rmation’. If the abnormal peak is found either in S- or C-window, the comment states that 
HbS or HbC variant respectively was detected.
Thus, only Hb variants could be sub-classifi ed to HbS, HbC, others (Hb variants apart from HbS or HbC), a 
combination of HbS with others and a combination of HbC with others. No additional confi rmatory testing, such 
as Hb analysis of samples containing Hb variant, was performed.
The Hb variants were also sub-classifi ed into those HbA1c results that could and could not be reported as a 
result of interferences. The criteria for non-reportable HbA1c are as follows:
i. The percentage of HbF >5%, or
ii. No HbA1c detected, or
iii. HbA1c peak area percentage < 4.1 % or more than >16.8%.
Data were analysed using the Statistical Package for Social Sciences (SPSS) software version 19.0. The 
percentage of Hb variant detected was determined by dividing the number of patients with Hb variant and the 
total number of patients with HbA1c result sent to HKL during that time period. From those with Hb variant, a 
Chi-Square test was used to analyse the association between gender and ethnicity with the type of Hb variants.
The study was approved by the Medical Research Ethics Committee of the Faculty of Medicine and Health 
Sciences, UPM, and also the ethical committee of the Ministry of Health, Malaysia.
RESULTS
Out of 13,139 HbA1c results analysed, 1,235 results were from the patients with more than one HbA1c result 
and thus, were excluded. Only 2.3% (273) of 11,904 patients were noted to have Hb variants. The demographic 
characteristics of all the patients and patients with Hb variants are presented in Tables 1 and 2, respectively. The 
majority of patients were Malays (50.7%) and there were more females (53.2%) compared to males (46.8%). 
Similarly, there was a higher percentage of Malays with Hb variants. A signifi cant association was found between 
Hb variants and ethnicity (p<0.05). The percentage of Malays who had Hb variants was 4%, followed by Indians 
(0.4%), and Chinese (0.2%).
The majority of Hb variants were the other variants (89%), followed by HbS (10.3%), and the combination 
of HbS with others (0.7%). There were no patients with HbC or its combination. For non-reportable HbA1c, six 
(2.2%) patients with Hb variants had HbA1c values of > 16.8%, while none had HbF > 5% or HbA1c < 4.1%.
DISCUSSION
DM is a worldwide health issue with prevalence increasing throughout the years. It was estimated that 171 million 
had DM in the year 2000 and this is projected to increase to 366 million in the year 2030[8]. In Malaysia, the 
prevalence of diabetes had doubled from 6.3% in 1986 to 11.6% in 2006[9]. These patients are at risk of developing 
chronic complications which are associated with signifi cant mortality and morbidity. Good glycaemic control 
reduces development of these complications with HbA1c widely used as a measure of glycaemic control. The 
normal HbA1c in those without DM is 4-6%. For diabetic patients, the recommended HbA1c is < 6.5%. Since 
HbA1c is measured as the percentage of total Hb, even small deviations in measurement lead to large changes in 
HbA1c value.
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In this paper, we report a percentage of Hb variants of 2.3%. In other parts of the world, the reported Hb variant 
detected during HbA1c analysis varies from as low as 0.03% in Korea, to as high as 3.1% in Brazil, depending on 
the method used and the population studied[10,11]. The co-inheritance of two or more Hb variants although uncommon 
can also be detected during HbA1c analysis. Six HbA1c results noted to have Hb variant were non-reportable, as 
the HbA1c results were > 16.8%, and this is possibly due to the effect of Hb variant. In these patients, it is advisable 
that another alternative method for HbA1c be used to better refl ect the patients’ glycaemic control.
The effect of Hb variant on HbA1c measurement depends on the type of Hb variant and the HbA1c method 
used. The effects of these variants on several commercially available HbA1c assays have been described over 
the years, particularly ones looking at common variants such as HbS, HbC HbE and HbD traits[12-16]. Nonetheless, 
no signifi cant differences in the HbA1c results were noted in several commercial HbA1c assays including the 
Biorad Variant II turbo assay used in our study when compared to a boronate affi nity method (CLC 330, Primus 
Diagnostics) in the presence of HbC or HbS traits[15]. CLC 330 has previously been shown to be unaffected by 
the presence of HbC and HbS traits[18]. In contrast, the presence of HbD and HbE trait gave higher HbA1c result 
when measured by Variant II Turbo[17].
Reporting of a falsely high or falsely low HbA1c result may lead to over-treatment or under-treatment of 
diabetes, respectively; both of which may lead to further complications. The laboratory should report the presence 
of Hb variant when it is detected, as recommended by the National Association of Clinical Biochemistry (NACB) 
guidelines 2002. However in 2009, only 39% of laboratories routinely reported the presence of Hb variants whilst 
some only reported when the variant had caused interferences to the test[19].
A possible interference by Hb variant should be suspected if the HbA1c value does not correlate with the 
patient’s clinical presentation or when the HbA1c result is >15%[1]. In addition, efforts should also be made to 
identify the Hb variant, while alternative HbA1c methods that are free of the interference should be used[1]. For 
situations in which the HbA1c values are unreliable, measurements of other glycated proteins such as fructosamine 
will provide another alternative.
Table 1. Demographic profi le of the patients with HbA1c 
Measurement from January 2010 to May 2010 in 
Hospital Kuala Lumpur 
 Profi le of patients Number of patients (%)
 Gender
 Male 5,566 (46.8)
 Female 6,338 (53.2)
 Ethnicity 
 Malay 6,031 (50.7)
 Chinese 2,479 (20.8)
 Indian 3,055 (25.7)
 Others 339 (2.8)
Table 2.  Types of Hb variant and its association with gender and ethnicity 
Patients profi le   n    HbS    Types of Variant HbS with  X2 p-value
   Others Others
Gender
 Male  130 17 (13.2%) 113 (86.9%) - 3.865* 0.145
 Female  143 11 (7.7%) 130 (90.9%) 2 (1.4%)  
Ethnicity
 Malay  243 19 (7.8%) 222 (91.4%) 2 (0.8%)
 Chinese  6 1 (16.7%) 5 (83.3%) - 36.152* 0.0
 Indian  11 7 (63.6%) 4 (36.4%) -
 Others  13 1 (7.7%) 12 (89.0%) -
* Chi-Square test
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In the current work, we did not perform further confi rmatory tests for Hb variants in those noted to have Hb 
variants during the HbA1c analysis, nor did we compare the effects of these variants on an alternative HbA1c 
method, which might limit the fi ndings of this study.
CONCLUSION
Hb variants were detected during routine HbA1c analysis in 2.3% of the patients. Only six of these variants were 
non-reportable with the current HbA1c method used. Although the percentage of Hb variants detected was low, 
their presence should be noted. Clinicians should be notifi ed of the Hb variants as these variants may alter the 
actual HbA1c values, and thus, not represent the true glycaemic control of patients with diabetes.
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